Renaissance Technologies’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Renaissance Technologies’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-134,700	Closed	-$21M	–	3788
2020 Q2	$21M	Buy	134,700 +29,600	+28%	+$4.5M	0.02%	792
2020 Q1	$15.2M	Sell	105,100 -137,000	-57%	-$26.4M	0.01%	924
2019 Q4	$49.5M	Buy	+242,100	New	+$44.2M	0.04%	525
2019 Q1	–	Sell	-99,300	Closed	-$5.57M	–	3765
2018 Q4	$5.57M	Buy	99,300 +79,798	+409%	+$4.87M	0.01%	1651
2018 Q3	$1.59M	Buy	+19,502	New	+$1.37M	﹤0.01%	2393
2017 Q3	–	Sell	-35,200	Closed	-$1.11M	–	3424
2017 Q2	$1.11M	Buy	35,200 +10,530	+43%	+$259K	﹤0.01%	2527
2017 Q1	$559K	Buy	+24,670	New	+$609K	﹤0.01%	2739

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Renaissance Technologies's RETA Position: Q3 2020 in Review

Renaissance Technologies sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 134,700 shares — an estimated $21M sold.

Renaissance Technologies first reported a position in RETA in Q1 2017 and held it in 7 quarters. The position peaked at $49.5M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Renaissance Technologies reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Renaissance Technologies sold 134,700 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $21M.
Renaissance Technologies first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 7 quarters.
Renaissance Technologies's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $49.5M in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Renaissance Technologies's 13F filing for Q3 2020, filed 13 Nov 2020.